CoChat

Phosphoinositide 3-Kinase Signaling Can Modulate MHC Class I and II Expression

Open access

The DOI matches its Crossref record; 69 of the 70 references it cites were found in a registry or an index.

Abstract

Abstract Molecular events activating the PI3K pathway are frequently detected in human tumors and the activation of PI3K signaling alters numerous cellular processes including tumor cell proliferation, survival, and motility. More recent studies have highlighted the impact of PI3K signaling on the cellular response to interferons and other immunologic processes relevant to antitumor immunity. Given the ability of IFNγ to regulate antigen processing and presentation and the pivotal role of MHC class I (MHCI) and II (MHCII) expression in T-cell–mediated antitumor immunity, we sought to determine the impact of PI3K signaling on MHCI and MHCII induction by IFNγ. We found that the induction of cell surface MHCI and MHCII molecules by IFNγ is enhanced by the clinical grade PI3K inhibitors dactolisib and pictilisib. We also found that PI3K inhibition increases STAT1 protein levels following IFNγ treatment and increases accessibility at genomic STAT1-binding motifs. Conversely, we found that pharmacologic activation of PI3K signaling can repress the induction of MHCI and MHCII molecules by IFNγ, and likewise, the loss of PTEN attenuates the induction of MHCI, MHCII, and STAT1 by IFNγ. Consistent with these in vitro studies, we found that within human head and neck squamous cell carcinomas, intratumoral regions with high phospho-AKT IHC staining had reduced MHCI IHC staining. Implications: Collectively, these findings demonstrate that MHC expression can be modulated by PI3K signaling and suggest that activation of PI3K signaling may promote immune escape via effects on antigen presentation.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1541-7786.mcr-19-0545

Cites

69 of 69 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 69 references

Research works printed but not linked: 1

  1. Meissner TB, Li A, Biswas A, Lee KH, Liu YJ, Bayir E, Iliopoulos D, van den Elsen PJ, Kobayashi KS. 2010 NLR family member NLRC5 is a transcriptional regulator of MHC class I genes. Proc Natl Acad Sci U S A 107: 13794– 9 20639463 PMC2922274

Cited by

See all 65

Metadata

Authors
Chandrasekaran, S., Sasaki, M., Scharer, C. D., Kissick, H. T., Patterson, D. G., Magliocca, K. R., Seykora, J. T., Sapkota, B., Gutman, D. A., Cooper, L. A., Lesinski, G. B., Waller, E. K., Thomas, S. N., Kotenko, S. V., Boss, J. M., Moreno, C. S., Swerlick, R. A., & Pollack, B. P.
Affiliations
  • Emory University (US)
  • Atlanta VA Medical Center (US)
  • University of Pennsylvania (US)
  • Georgia Institute of Technology (US)
  • Rutgers New Jersey Medical School (US)
Corresponding author
Pollack, Brian P.
Venue
Molecular Cancer Research
Published
2019-12-01
Volume
17
Issue
12
Pages
2395-2409
ISSN
  • 1541-7786 (ISSN-L)
  • 1557-3125
OpenAlex
W2976327003
Cited by
61
References
70
Citations by year
2026: 6 · 2025: 9 · 2024: 12 · 2023: 7 · 2022: 11 · 2021: 13 · 2020: 3
FWCI
2.23
Type
journal article
Language
en
Open access
Locations
  • Molecular Cancer Research (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • U.S. Department of Veterans Affairs (1I01BX001922-01A1)
  • Office of Extramural Research, National Institutes of Health (5P50CA128613-05, 5R01CA207619-03, T32CA160040, P30CA138292, UL1TR002378)
  • Winship Cancer Institite (Skin cancer and melanona fund)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Immunology and Microbiology › Immunology › Cytokine Signaling Pathways and Interactions
Keywords
phosphoinositide 3-kinase signaling, MHC class I expression, MHC class II expression, interferon-gamma, STAT1, PI3K inhibitors, dactolisib, pictilisib, PTEN, antigen processing and presentation, antitumor immunity, immune evasion, head and neck squamous cell carcinoma, Akt phosphorylation
MeSH terms
Squamous Cell Carcinoma of Head and Neck, Binding Sites, DNA-Binding Proteins, Genes, MHC Class II, Genes, MHC Class I, Humans, Interferon-gamma, Protein Binding, Signal Transduction, Gene Expression Regulation, Neoplastic, Antigen Presentation, Genomics, Protein Kinase Inhibitors, Cell Proliferation, STAT1 Transcription Factor, Proto-Oncogene Proteins c-akt, PTEN Phosphohydrolase, Phosphatidylinositol 3-Kinase

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Phosphoinositide 3-Kinase Signaling Can Modulate MHC Class I and II Expression. https://app.cochat.ai/papers/10.1158/1541-7786.mcr-19-0545
The paper
Chandrasekaran, S., Sasaki, M., Scharer, C. D., Kissick, H. T., Patterson, D. G., Magliocca, K. R., Seykora, J. T., Sapkota, B., Gutman, D. A., Cooper, L. A., Lesinski, G. B., Waller, E. K., Thomas, S. N., Kotenko, S. V., Boss, J. M., Moreno, C. S., Swerlick, R. A., & Pollack, B. P. (2019). Phosphoinositide 3-Kinase Signaling Can Modulate MHC Class I and II Expression. Molecular Cancer Research. https://doi.org/10.1158/1541-7786.mcr-19-0545

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.